-The Economic Times NEW DELHI: The Manmohan Singh government's target of skilling 500 million people by 2022 is grossly inflated and is based on a speech by late management guru CK Prahalad instead of any demographic analysis. The country would actually need only about half that number of trained manpower by then, the government's own think-tank, the Institute of Applied Manpower Research (IAMR), has said in a research paper. The IAMR, housed under...

-The Economic Times The World Trade Organisation (WTO) has honoured renowned economist and globalisation buff Jagdish N Bhagwati by inducting him into its Hall of Fame. The professor of economics and law at Columbia University, Bhagwati is the author of books as seminal as 'In Defence of Globalisation' and 'The Wind of the Hundred Days: How Washington Mismanaged Globalisation'. He spoke to ET about his decades-long campaign for trade liberalisation, his...

-The Hindu Business Line   The Bill does not take into account the extremely varied nature of land markets. It looks like the Land Acquisition, Rehabilitation And Resettlement Bill is going to be finally presented in Parliament for passage in the current session. The full details of what is in the current Bill aren't known because over 150 amendments may have been made to the last version that was available for public scrutiny. But...

-The Hindu Business Line After the 1980s, special interest groups have preferred to knock on the doors of the judiciary. In India today, matters of public interest seem to get their due only when the Supreme Court has added its two cents. Interest groups, representing both general and special interests, petition the judiciary actively. In an era where virtually all institutions in India have been vulnerable to political capture, the judiciary seems like...

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...